CellVax Therapeutics
Miami, US · Founded 2020 · Delaware corporation
CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
BiotechHealthtechMedical Devices
Founders & leadership
CellVax Therapeutics was founded in 2020 by Fernando Kreutz.
FK
Fernando KreutzFounder & CEO, Board of Directors
EV
Emerson von der GoltzCFO, Board of Directors
Board
AD
Alberto da Costa SteinBoard director
AS
Alberto SteinMedical Adviser, Board of Directors
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 round · 2024
▶$2.1MraisedOct 2024 · 1 investors · OtherRule 506(b)
▶$2.1MraisedOct 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Fernando KreutzExecutive Officer, Director
- Alberto da Costa SteinDirector
- Offering amount
- $5M
- Amount sold
- $2.1M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapDynavax NASDAQ: DVAX www.dynavax.com15 shared keywordsDynavax is a biopharmaceutical company that develops and commercializes vaccines to protect against infectious diseases, including HEPLISAV-B, a two-dose adult hepatitis B vaccine, and its CpG 1018 adjuvant used in multiple vaccines. The company also advances a pipeline of novel vaccine clinical candidates.
CancerVAX14 shared keywordsCancerVax is a pre-clinical biotech company developing a customizable, AI-supported cancer immunotherapy platform delivered as an injection, designed to disguise cancer cells as a familiar virus (such as measles) so the body's immune system recognizes and kills them. The platform aims to treat many types of cancer and is being developed with partners including Cytiva and TriLink BioTechnologies.
Centivax10 shared keywordsCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
Imvax10 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Abivax9 shared keywordsAbivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
Vaccinex9 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Companies competing with CellVax Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CellVax Therapeutics do?
- CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
- Who founded CellVax Therapeutics?
- CellVax Therapeutics was founded by Fernando Kreutz in 2020.
- How much funding has CellVax Therapeutics raised?
- CellVax Therapeutics has disclosed $2.1M raised across 1 round.
- Where is CellVax Therapeutics headquartered?
- CellVax Therapeutics is headquartered in Miami, US.